UNSPSC 51311811: Emedastine difumarate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H26N4O.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42MB94QOSM, chemically known as 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1h-1,4-diazepin-1-yl)benzimidazole fumarate (1:2), but more generally known as emedastine difumarate, which bears US NIH Compound Identifier 5282485. European Medicines Agency schedules emedastine difumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06503MIG.

UNSPSC 51311811 Emedastine difumarate is a Commodity code that maps to specific pharmaceutical preparations, but recent state and local procurement activity under this code shows minimal direct alignment. The three most recently posted opportunities cite this code yet solicit naloxone and drug deactivation systems, a direct-to-manufacturer prescription initiative, and generic multi-source pharmaceuticals with over-the-counter products — none of which target emedastine difumarate specifically. The mismatch suggests either miscoding by issuing bodies or that emedastine procurement, when it occurs, is bundled under broader pharmaceutical commodity codes rather than solicited as a standalone product line.

State and local health authorities are the primary issuing bodies, including county health departments (Seminole County, Florida), state human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). Activity appears concentrated in Texas, Florida, and Minnesota, with the MMCAP procurement also covering Oregon. The Seminole County IFB (IFB60459723LAS, response deadline July 26, 2023) sought naloxone and drug deactivation systems through electronic bidding with quarterly deliveries; the Texas HHS RFI (HHS0017013, April 3, 2026) explored direct-to-manufacturer prescription contracting; and the MMCAP RFP (S1070000015802, due March 26, 2026) solicited generic pharmaceuticals and OTC products across authorized wholesaler channels requiring cGMP and DSCSA compliance. Given the code's minimal recent relevance to actual procurement under its stated product name, business development professionals should verify whether opportunities tagged to this code truly target emedastine or represent issuing-body administrative miscoding before investing pre-bid effort.